Zoono Group Limited (ASX:ZNO) is pleased to advise that it has received the report for the laboratory tests undertaken against COVID-19. The results show that Zoono’s Z-71 Microbe Shield is > 99.99% effective against feline coronavirus (the recognised surrogate for COVID-19).
COVID-19 has become a global concern, in particular as it has been shown to survive on surfaces for up to 9 days.
Zoono products have been successfully tested against a variety of pathogens for up to 30 days on surfaces and 24 hours on hands.
Whilst Zoono had been previously tested against bovine coronavirus (the nominated surrogate for MERS), this latest strain required new testing.
Two separate tests were completed to EN Standard 14476:2013+A2:2019. The first was against Vaccinia, sometimes referred to as the ‘mother ship’ of double enveloped viruses(that are particularly hard to inactivate); with the subsequent test against the nominated (and globally accepted) surrogate for COVID-19, feline coronavirus.
EN14476 is the European Standard that applies to products within the medical area including hygienic hand rubs, hygienic hand wash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means.
RESULTS: The test against Vaccinia confirmed efficacy of > 4Log (greater than 99.99% efficacy) for Zoono Z-71 Microbe Shield.
The second test against the COVID-19 surrogate, feline coronavirus, confirmed efficacy at 4.33Log (greater than 99.99% efficacy).
The members of the family Coronaviridae are enveloped and have positive sense RNA genome. Coronaviruses have a distinct morphology with an outer ‘corona’ of embedded envelope spikes. These viruses cause a broad spectrum of animal and human disease and are particularly difficult to inactivate.
Zoono is very pleased with the results which further demonstrates the ability of the Zoono technology to be part of the solution to prevent and protect against the spread of the COVID19 Virus.